The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Dihydroartemisinin–Piperaquine for the Prevention of Malaria in Pregnancy
Open accessAbstract
BACKGROUND: Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa. However, with the spread of resistance to sulfadoxine-pyrimethamine, new interventions are needed. METHODS: We conducted a double-blind, randomized, controlled trial involving 300 human immunodeficiency virus (HIV)-uninfected pregnant adolescents or women in Uganda, where sulfadoxine-pyrimethamine resistance is widespread. We randomly assigned participants to a sulfadoxine-pyrimethamine regimen (106 participants), a three-dose dihydroartemisinin-piperaquine regimen (94 participants), or a monthly dihydroartemisinin-piperaquine regimen (100 participants). The primary outcome was the prevalence of histopathologically confirmed placental malaria. RESULTS: The prevalence of histopathologically confirmed placental malaria was significantly higher in the sulfadoxine-pyrimethamine group (50.0%) than in the three-dose dihydroartemisinin-piperaquine group (34.1%, P=0.03) or the monthly dihydroartemisinin-piperaquine group (27.1%, P=0.001). The prevalence of a composite adverse birth outcome was lower in the monthly dihydroartemisinin-piperaquine group (9.2%) than in the sulfadoxine-pyrimethamine group (18.6%, P=0.05) or the three-dose dihydroartemisinin-piperaquine group (21.3%, P=0.02). During pregnancy, the incidence of symptomatic malaria was significantly higher in the sulfadoxine-pyrimethamine group (41 episodes over 43.0 person-years at risk) than in the three-dose dihydroartemisinin-piperaquine group (12 episodes over 38.2 person-years at risk, P=0.001) or the monthly dihydroartemisinin-piperaquine group (0 episodes over 42.3 person-years at risk, P<0.001), as was the prevalence of parasitemia (40.5% in the sulfadoxine-pyrimethamine group vs. 16.6% in the three-dose dihydroartemisinin-piperaquine group [P<0.001] and 5.2% in the monthly dihydroartemisinin-piperaquine group [P<0.001]). In each treatment group, the risk of vomiting after administration of any dose of the study agents was less than 0.4%, and there were no significant differences among the groups in the risk of adverse events. CONCLUSIONS: The burden of malaria in pregnancy was significantly lower among adolescent girls or women who received intermittent preventive treatment with dihydroartemisinin-piperaquine than among those who received sulfadoxine-pyrimethamine, and monthly treatment with dihydroartemisinin-piperaquine was superior to three-dose dihydroartemisinin-piperaquine with regard to several outcomes. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; ClinicalTrials.gov number, NCT02163447.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malaria in pregnancy: pathogenesis and immunity
Rogerson, S. J., Hviid, L., Duffy, P. E., Leke, R. F., & Taylor, D. W. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70022-1 · Cited by 628
Quantifying the Number of Pregnancies at Risk of Malaria in 2007: A Demographic Study
Dellicour, S., Tatem, A. J., Guerra, C. A., Snow, R. W., & ter Kuile, F. O. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000221 · Cited by 490
Guyatt, H., & Snow, R. (2001) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2001.64.36 · Cited by 252
Kayentao, K., Kodio, M., Newman, R. D., Maiga, H., Doumtabe, D., Ongoiba, A., Coulibaly, D., Keita, A. S., Maiga, B., Mungai, M., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/426400 · Cited by 162
Harrington, W. E., Mutabingwa, T. K., Kabyemela, E., Fried, M., & Duffy, P. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir376 · Cited by 156
Cottrell, G., Moussiliou, A., Luty, A. J. F., Cot, M., Fievet, N., Massougbodji, A., Deloron, P., & Tuikue Ndam, N. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ122 · Cited by 151
Muehlenbachs, A., Fried, M., McGready, R., Harrington, W. E., Mutabingwa, T. K., Nosten, F., & Duffy, P. E. (2010) · The Journal of Infectious Diseases · doi:10.1086/656723 · Cited by 100
Self-citationPiola, P., Nabasumba, C., Turyakira, E., Dhorda, M., Lindegardh, N., Nyehangane, D., Snounou, G., Ashley, E. A., McGready, R., Nosten, F., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70202-4 · Cited by 99
Cohee, L. M., Kalilani-Phiri, L., Boudova, S., Joshi, S., Mukadam, R., Seydel, K. B., Mawindo, P., Thesing, P., Kamiza, S., Makwakwa, K., et al. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-274 · Cited by 75
Self-citationBertin, G., Briand, V., Bonaventure, D., Carrieu, A., Massougbodji, A., Cot, M., & Deloron, P. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-196 · Cited by 37
Cited by
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic
Blasco, B., Leroy, D., & Fidock, D. A. (2017) · Nature Medicine · doi:10.1038/nm.4381 · Cited by 576
Antimalarial drug resistance in Africa: the calm before the storm?
Conrad, M. D., & Rosenthal, P. J. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30261-0 · Cited by 255
Fried, M., & Duffy, P. E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025551 · Cited by 202
An overview of malaria in pregnancy
Bauserman, M., Conroy, A. L., North, K., Patterson, J., Bose, C., & Meshnick, S. (2019) · Seminars in Perinatology · doi:10.1053/j.semperi.2019.03.018 · Cited by 167
Moore, K. A., Simpson, J. A., Scoullar, M. J. L., McGready, R., & Fowkes, F. J. I. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30340-6 · Cited by 165
Metadata
- Authors
- Kakuru, A., Jagannathan, P., Muhindo, M. K., Natureeba, P., Awori, P., Nakalembe, M., Opira, B., Olwoch, P., Ategeka, J., Nayebare, P., Clark, T. D., Feeney, M. E., Charlebois, E. D., Rizzuto, G., Muehlenbachs, A., Havlir, D. V., Kamya, M. R., & Dorsey, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-10
- Volume
- 374
- Issue
- 10
- Pages
- 928-939
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2294130235
- Cited by
- 228
- References
- 10
- FWCI
- 26.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dihydroartemisinin–Piperaquine for the Prevention of Malaria in Pregnancy. https://app.cochat.ai/papers/10.1056/nejmoa1509150
- The paper
- Kakuru, A., Jagannathan, P., Muhindo, M. K., Natureeba, P., Awori, P., Nakalembe, M., Opira, B., Olwoch, P., Ategeka, J., Nayebare, P., Clark, T. D., Feeney, M. E., Charlebois, E. D., Rizzuto, G., Muehlenbachs, A., Havlir, D. V., Kamya, M. R., & Dorsey, G. (2016). Dihydroartemisinin–Piperaquine for the Prevention of Malaria in Pregnancy. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1509150
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.